Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases

被引：18

作者：

Westman-Brinkmalm, Ann ^{[1
]}

Ruetschi, Ulla ^{[2
]}

Portelius, Erik ^{[1
]}

Andreasson, Ulf ^{[1
]}

Brinkmalm, Gunnar ^{[1
]}

Karlsson, Gosta ^{[1
]}

Hansson, Sara ^{[1
]}

Zetterberg, Henrik ^{[1
]}

Blennow, Kaj ^{[1
]}

机构：

[1] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, S-43180 Molndal, Sweden

[2] Univ Gothenburg, Sahlgrenska Acad, Dept Clin Chem & Transfus Med, Inst Lab Med, S-43180 Molndal, Sweden

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2009年 / 14卷

基金：

瑞典研究理事会;

关键词：

Alzheimer's disease; Frontotemporal Dementia; Cerebrospinal Fluid; Multiple Sclerosis; Proteomics; Review; LASER-DESORPTION/IONIZATION-TIME; FLIGHT-MASS-SPECTROMETRY; HUMAN CEREBROSPINAL-FLUID; ONSET ALZHEIMER-DISEASE; AMYLOID-BETA PEPTIDES; 2-DIMENSIONAL GEL-ELECTROPHORESIS; MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E GENOTYPE; MULTIPLE-SCLEROSIS; FRONTOTEMPORAL DEMENTIA;

D O I：

10.2741/3341

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Neurodegenerative diseases are characterized by premature neuronal loss in specific brain regions. During the past decades our knowledge on molecular mechanisms underlying neurodegeneration has increased immensely and resulted in promising drug candidates that might slow down or even stop the neuronal loss. These advances have put a strong focus on the development of diagnostic tools for early or pre-clinical detection of the disorders. In this review we discuss our experience in the field of neuroproteomics/peptidomics, with special focus on biomarker discovery studies that have been performed on CSF samples from well-defined patient and control populations.

引用

页码：1793 / 1806

页数：14

共 90 条

[1] Abdi F, 2006, J ALZHEIMERS DIS, V9, P293
[2] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
Andreasen, N
Hesse, C
Davidsson, P
Minthon, L
Wallin, A
Winblad, B
Vanderstichele, H
Vanmechelen, E
Blennow, K
[J]. ARCHIVES OF NEUROLOGY, 1999, 56 (06) : 673 - 680
[3] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N
Minthon, L
Davidsson, P
Vanmechelen, E
Vanderstichele, H
Winblad, B
Blennow, K
[J]. ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 373 - 379
[4] Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
Arai, H
Morikawa, Y
Higuchi, M
Matsui, T
Clark, CM
Miura, M
Machida, N
Lee, VMY
Trojanowski, JQ
Sasaki, H
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (02) : 262 - 264
[5] ARROYAVE G, 1979, ARCH LATINOAM NUTR, V29, P233
[6] Generation of C-terminally truncated amyloid-β peptides is dependent on γ-secretase activity
Beher, D
Wrigley, JDJ
Owens, AP
Shearman, MS
[J]. JOURNAL OF NEUROCHEMISTRY, 2002, 82 (03) : 563 - 575
[7] Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment:: Indication of carrier-mediated epitope masking of amyloid β peptides
Bibl, M
Esselmann, H
Otto, M
Lewczuk, P
Cepek, L
Rüther, E
Kornhuber, J
Wiltfang, J
[J]. ELECTROPHORESIS, 2004, 25 (17) : 2912 - 2918
[8] BLENNOW K, 1993, ACTA NEUROL SCAND, V88, P221
[9] Blennow K, 1994, Int Psychogeriatr, V6, P13, DOI 10.1017/S1041610294001584
[10] Blennow K, 1994, INT PSYCHOGERIATR, V6, P59

← 1 2 3 4 5 6 7 8 9 →